Literature DB >> 12937125

Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.

Stefan Kins1, Pascal Kurosinski, Roger M Nitsch, Jürgen Götz.   

Abstract

A reduced activity of protein phosphatase 2A (PP2A) has been shown in brains of patients with Alzheimer's disease (AD), a neurodegenerative disorder characterized histopathologically by amyloid plaques and neurofibrillary tangles. Tau, as the principal component of neurofibrillary tangles, can be hyperphosphorylated by a reduced activity of PP2A in vitro and by pharmacological approaches, suggesting a crucial role of PP2A in tangle formation. To dissect the role of PP2A in vivo, we previously generated transgenic mice with chronically reduced PP2A activity by expressing a dominant-negative mutant form of the PP2A catalytic subunit Calpha, L199P, under the control of a neuron-specific promoter. In these mice, endogenous tau is phosphorylated at the epitopes Ser202/Thr205 and Ser422. In vitro, these tau phospho-epitopes can be phosphorylated by the kinases ERK and JNK, and the kinases themselves are negatively regulated by PP2A. In this study, we show that chronic inhibition of PP2A activity in L199P transgenic mice causes the activation of ERK and JNK as demonstrated by the phosphorylation and nuclear accumulation of the ERK and JNK substrates, Elk-1 and c-Jun. TUNEL staining revealed that activated JNK signaling was not associated with cell death. Our findings imply that PP2A is a negative regulator of the ERK and JNK signaling pathways in vivo, suggesting that in AD, tau hyperphosphorylation may be caused in part by PP2A dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937125      PMCID: PMC1868255          DOI: 10.1016/S0002-9440(10)63444-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  63 in total

Review 1.  Protein phosphatase 2A: the Trojan Horse of cellular signaling.

Authors:  E Sontag
Journal:  Cell Signal       Date:  2001-01       Impact factor: 4.315

2.  PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus.

Authors:  V Vogelsberg-Ragaglia; T Schuck; J Q Trojanowski; V M Lee
Journal:  Exp Neurol       Date:  2001-04       Impact factor: 5.330

3.  Distinct role of protein phosphatase 2A subunit Calpha in the regulation of E-cadherin and beta-catenin during development.

Authors:  J Götz; A Probst; C Mistl; R M Nitsch; E Ehler
Journal:  Mech Dev       Date:  2000-05       Impact factor: 1.882

4.  Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.

Authors:  C X Gong; T Lidsky; J Wegiel; L Zuck; I Grundke-Iqbal; K Iqbal
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

5.  Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5.

Authors:  K Iijima; K Ando; S Takeda; Y Satoh; T Seki; S Itohara; P Greengard; Y Kirino; A C Nairn; T Suzuki
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

6.  BDNF diminishes caspase-2 but not c-Jun immunoreactivity of neurons in retinal ganglion cell layer after transient ischemia.

Authors:  T Kurokawa; N Katai; H Shibuki; S Kuroiwa; Y Kurimoto; C Nakayama; N Yoshimura
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-11       Impact factor: 4.799

7.  The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling.

Authors:  T P Shanley; N Vasi; A Denenberg; H R Wong
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

8.  Increased expression and activation of stress-activated protein kinases/c-Jun NH(2)-terminal protein kinases in atherosclerotic lesions coincide with p53.

Authors:  B Metzler; Y Hu; H Dietrich; Q Xu
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

9.  Tau filament formation in transgenic mice expressing P301L tau.

Authors:  J Götz; F Chen; R Barmettler; R M Nitsch
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

10.  Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.

Authors:  C Atzori; B Ghetti; R Piva; A N Srinivasan; P Zolo; M B Delisle; S S Mirra; A Migheli
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

View more
  52 in total

Review 1.  Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.

Authors:  Lian-Feng Lin; Huan-Min Luo
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Different mechanisms account for extracellular-signal regulated kinase activation in distinct brain regions following global ischemia and reperfusion.

Authors:  Y Ho; E Logue; C W Callaway; D B DeFranco
Journal:  Neuroscience       Date:  2007-01-04       Impact factor: 3.590

4.  Mechanism of okadaic acid-induced neuronal death and the effect of estrogens.

Authors:  Kun Don Yi; Douglas F Covey; James W Simpkins
Journal:  J Neurochem       Date:  2008-11-28       Impact factor: 5.372

Review 5.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

6.  PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.

Authors:  Pietri Puustinen; Melissa R Junttila; Sari Vanhatupa; Anna A Sablina; Melissa E Hector; Kaisa Teittinen; Olayinka Raheem; Kirsi Ketola; Shujun Lin; Juergen Kast; Hannu Haapasalo; William C Hahn; Jukka Westermarck
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

7.  Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.

Authors:  Jin-Jing Pei; Cheng-Xin Gong; Wen-Lin An; Bengt Winblad; Richard F Cowburn; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 8.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

9.  An update on the toxicity of Abeta in Alzheimer's disease.

Authors:  Jürgen Götz; Lars M Ittner; Nicole Schonrock; Roberto Cappai
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.

Authors:  Abdur Rahman; Kaka Ting; Karen M Cullen; Nady Braidy; Bruce J Brew; Gilles J Guillemin
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.